Bridging Clinical Research Gaps: How Site Augmentation Enhances Trial Success

Understanding how site augmentation services could be leveraged to overcome challenges is not the responsibility of one entity. The most creative and effective solutions arise from collaboration among all stakeholders — sponsors, CROs, service providers, and research sites. The post Bridging Clinical Research Gaps: How Site Augmentation Enhances Trial Success appeared first on MedCity News.

Read More

Navigating Co-Occurring ADHD and Eating Disorders

Co-occurring ADHD and eating disorders can intensify the symptoms of each other. Impulsivity can lead to binge eating or purging and emotional dysregulation can make it challenging to cope with life’s difficulties. Addressing both ADHD and an eating disorder at the same time can best forge the path to recovery and healthy coping.  The post…

Read More

Limitados por políticas de Trump, los registros de cáncer solo reconocerán a pacientes como “hombre” o “mujer”

Las máximas autoridades en estadísticas del cáncer de Estados Unidos pronto deberán clasificar el sexo de los pacientes estrictamente como hombre, mujer o desconocido, un cambio que, según científicos y defensores de pacientes, afectará negativamente la salud de la población transgénero, una de las más marginadas del país. Médicos y activistas por los derechos de…

Read More

Healthcare AI Is Only As Good As the Systems That Govern It

AI doesn’t just demand better processes. It requires a complete redesign of traditional healthcare operations for a new level of precision, traceability, and governance. A new operating model that the vast majority of healthcare organizations simply aren’t built around today. The post Healthcare AI Is Only As Good As the Systems That Govern It appeared…

Read More

AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy

Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are important because many patients do not live long enough to receive a second-line cancer therapy. The post AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line…

Read More